Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a post hoc analysis based on a phase III trial
A lower BMI is associated with a greater treatment response and quality of life in moderate-to-severe plaque psoriasis patients receiving vunakizumab.
Authors
- L. Li
- Xiunan Wang (ORCID: https://orcid.org/0000-0003-4070-4101)
Institutions
- Capital Medical University (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fphar.2025.1685072
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00